A Phase 3 interventional study of Mecobalamin in Peripheral Neuropathy Due to Chemotherapy and Peripheral Neuropathy, Chemotherapy-induced, sponsored by Qinghai Red Cross Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Qinghai Red Cross Hospital · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Peripheral Nervous System Diseases with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Peripheral Nervous System Diseases · China.
Among the 18 studies in Peripheral Nervous System Diseases with a site in China, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 3, and was the 15th registered.
476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.
Browse Peripheral Nervous System Diseases studies →5 of the 18 studies in Peripheral Nervous System Diseases with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18+
Affiliated Hospital of Qinghai University · Sites in China
Ages 18+
Affiliated Hospital of Qinghai University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2010; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 326 is above the median of 57 across 359 interventional studies indexed under Peripheral Nervous System Diseases.
Median enrollment 109 across the 14 interventional studies, 54 across the 4 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
Qinghai Red Cross Hospital is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Qinghai Red Cross Hospital has 1 study filed under Peripheral Nervous System Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Peripheral Nervous System Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.
This is a prospective, multicenter, open-label randomized controlled trial to evaluate oral mecobalamin for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients with solid tumors receiving taxane-based chemotherapy. Participants are assigned to receive prophylactic mecobalamin (0.5 mg orally three times daily, starting on the first day of taxane-based chemotherapy and continuing until chemotherapy completion) or no routine mecobalamin prophylaxis. The primary endpoint is the cumulative incidence of grade ≥2 CIPN (CTCAE v6.0) from randomization to the end of chemotherapy.
Secondary endpoints include measures of CIPN onset and severity, patient-reported outcomes (PROs), chemotherapy delivery, and safety. Study assessments are conducted at baseline and during each chemotherapy cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive oral mecobalamin 0.5 mg three times daily (total 1.5 mg/day), starting on the first day of taxane chemotherapy and continuing until completion of chemotherapy. If CIPN-related symptoms (e.g., pain, paresthesia) occur, the treating physician will provide standard symptomatic treatment in accordance with current clinical guidelines.
Drug: Mecobalamin
Participants do not receive routine mecobalamin prophylaxis. Follow-up schedule, education, and outcome assessments are the same as in the mecobalamin group. If CIPN-related symptoms (e.g., pain, paresthesia) occur, the treating physician will provide standard symptomatic treatment in accordance with current clinical guidelines.
Oral mecobalamin tablets, 0.5 mg three times daily (total 1.5 mg/day), starting on Day 1 of taxane-based chemotherapy and continuing until completion of chemotherapy, administered as prophylaxis for chemotherapy-induced peripheral neuropathy. Participants in both groups are not permitted to use any other medications or supplements specifically for the prophylaxis of CIPN during the study period. However, if CIPN-related symptoms (e.g., pain, paresthesia) occur, the treating physician will provide standard symptomatic treatment in accordance with current clinical guidelines.
Cumulative incidence of grade ≥2 chemotherapy induced peripheral neuropathy (CIPN)
Defined as the proportion of participants who experience grade ≥2 CIPN (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Cumulative incidence of any grade CIPN
Defined as the proportion of participants who experience CIPN of any grade (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Median time to first occurrence of grade ≥2 CIPN
Defined as the median time from randomization to the first occurrence of grade ≥2 CIPN (assessed by CTCAE v6.0). Participants without grade ≥2 CIPN will be censored at the end of chemotherapy (or earlier discontinuation).
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Cumulative incidence of grade 2 CIPN
Defined as the proportion of participants who experience grade 2 CIPN (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Cumulative incidence of grade ≥3 CIPN
Defined as the proportion of participants who experience grade ≥3 CIPN (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Changes in EORTC QLQ-CIPN20 scores over time
The European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20-item questionnaire (EORTC QLQ-CIPN20) is a validated patient-reported outcome instrument assessing CIPN-related symptoms and functional impairment. It includes 20 items covering sensory, motor, and autonomic symptoms, each rated on a 4-point Likert scale. Raw scores are linearly transformed to 0 to 100 points according to the EORTC scoring manual; higher scores indicate worse symptom burden and functional limitations. The questionnaire will be administered at multiple time points to characterize the trajectory of CIPN during and after chemotherapy.
Time frame: Baseline; during each chemotherapy cycle; end of chemotherapy (up to 24 weeks); and 1 week, 1 month, and 6 months after chemotherapy completion.
Changes in EQ-5D-5L scores over time
The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a standardized instrument for measuring health-related quality of life. It consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each with five levels. EQ-5D-5L responses will be converted to a single utility index score using the China EQ-5D-5L value set (1 = full health; 0 = dead; values may be \< 0); higher index scores indicate better health. The EQ-5D-5L also includes a vertical visual analogue scale (VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health); higher VAS scores indicate better self-rated health. Both the index score and VAS score will be assessed at multiple time points to evaluate changes in health-related quality of life during and after chemotherapy.
Time frame: Baseline; mid-treatment (at the midpoint of planned chemotherapy cycles, up to 12 weeks), end of chemotherapy (up to 24 weeks); and 1 week, 1 month, and 6 months after chemotherapy completion.
Proportion of participants with taxane chemotherapy dose modification due to CIPN
Defined as the proportion of participants who have taxane dose reduction, dose delay, or treatment discontinuation attributable to CIPN during the taxane chemotherapy period.
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Relative dose intensity (RDI) of taxane chemotherapy
Defined as the relative dose intensity of taxane chemotherapy over the planned treatment period (actual dose intensity relative to the protocol/planned dose intensity), summarized for each participant.
Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Incidence and severity of AEs and SAEs occurring during the study.
Time frame: From randomization through 6 months after chemotherapy completion.
Change in lower-limb sensory nerve conduction velocity (SNCV) assessed by nerve conduction studies (NCS)
Change in lower-limb SNCV (m/s) assessed by NCS. NCS will be performed on the sural sensory nerve using standard surface stimulation and recording electrodes, following harmonized procedures across sites where NCS is performed. SNCV will be calculated from sensory nerve latency (ms) and the stimulation-to-recording distance; sensory nerve action potential (SNAP) amplitude (μV) and latency (ms) will also be recorded. Testing is optional and will be performed in a subset of participants at selected sites where NCS equipment and trained personnel are available.
Time frame: Baseline and end of chemotherapy (up to 24 weeks).
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in publications will be shared with qualified researchers upon reasonable request. Shared IPD will include participant-level data on baseline characteristics, treatment exposure, primary and secondary outcome measures, and safety outcomes. Requests must include a scientifically sound research proposal and analysis plan. Access will be granted after approval by the study steering committee and completion of a data use agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning after publication of the primary results and available for 3 years.
Access criteria: De-identified IPD and supporting documents will be made available to qualified researchers upon submission of a scientifically valid research proposal to the corresponding author. Access requires approval by the study steering committee and the completion of a data use agreement to ensure appropriate data use and participant confidentiality.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mecobalamin
Peripheral Nervous System Diseases →
Qinghai Red Cross Hospital